CREB3L2 and Miyoshi myopathy: By integrating CREB3L2‐target networks with a curated angiogenesis gene set, we constructed and internally validated a robust LASSO–Cox prognostic signature that accurately stratifies MM patients into high‐risk and low‐risk cohorts.